• Chugai signed an exclusive worldwide license with GSK for anti-dengue antibody AID351 on Aug. 17, 2026.
• GSK gains rights to develop, manufacture, commercialize AID351 for flavivirus infections, including dengue fever.
• Clinical development shifts to GSK, including Phase I trials; manufacturing also moves to GSK.
• Chugai to receive royalties on future sales; also eligible for a share of any third-party sublicensing income.
• Deal follows a Jan. 30, 2025 collaboration agreement; program originated from work with A*STAR SIgN and National University of Singapore.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Chugai Pharmaceutical Co. Ltd. published the original content used to generate this news brief on August 18, 2026, and is solely responsible for the information contained therein.